Could a common arthritis drug tame rare immune disease symptoms?

NCT ID NCT07262983

Recruiting now Disease control Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Aug 14, 2026 · Updated 34 times

Summary

This early study tests baricitinib, a drug already approved for other immune conditions, in 20 people with Job syndrome who also have lupus-like disease or eczema. Participants take the pill daily for 6 months. The main goal is to see if it is safe and tolerable, while also checking for any improvement in skin and lupus symptoms.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: baricitinib (a tablet taken by mouth, approved for other immune diseases)
What this could lead to: If it works, this could point toward a treatment that reduces lupus-like symptoms and eczema in people with Job syndrome.
What could go wrong: This is a very early, small pilot study with only 20 participants. It is designed mainly to check safety, not to prove effectiveness. The drug may not improve symptoms and could cause side effects like infections.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ATOPIC DERMATITIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

atopic eczema hyper-IgE recurrent infection syndrome 1, autosomal dominant hyper-IgE syndrome lupus erythematosus systemic lupus erythematosus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ATOPIC DERMATITIS HIES HYPER IGE SYNDROME FROM STAT3 MUTATION JOB S SYNDROME LUPUS

Contacts and locations

Locations

National Institutes of Health Clinical Center
RECRUITING

Bethesda, Maryland, 20892, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.